Weight-loss surgery trumps popular Ozempic treatment in shocking new comparison

Weight-loss surgery was shown to be five times more effective than weekly injections of popular GLP-1 receptor agonists, including semaglutide (such as Ozempic) and tirzepatide (such as Mounjaro).

The finding comes from a recent study presented this week at the American Society for Metabolic and Bariatric Surgery (ASMBS) 2025 Annual Scientific Meeting in Washington.

Researchers looked at "real-world" electronic medical record data of 51,085 patients at NYU Langone Health and NYC Health + Hospitals.